Xeris expects 2022 net product revenue at top of $105M-$110M guidance, cash >$120M

Xeris Biopharma Holdings, Inc.

2022-FY EPS reported -$0.70 revenue$110,248,000

Expects 2022 net product revenue at top of guidance range of $105M-$110M.
Year-end cash, cash equivalents, and short-term investments >$120M, above previous $110M-$120M range.
FDA approved a generic version of Keveyis (dichlorphenamide); company believes it can defend the franchise.
Does not anticipate need to raise equity to fund operations, citing commercial momentum and cash position.
Q4 and FY22 financial results to be reported on or about March 8, 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Xeris Biopharma Holdings, Inc. updated its the year ended December 31, 2022 guidance (reaffirmed).

Period: the year ended December 31, 2022
Guidance: reaffirmed
Result: preliminary results

Exact text from the filing

XERIS BIOPHARMA UPDATES ITS OUTLOOK FOR 2022 Company expects to end 2022 with over $120M in cash, cash equivalents, and short-term investments and at the top of its net product revenue guidance of $105M-$110M

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

Xeris Biopharma Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001867096-23-000003

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.